The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation - PubMed (original) (raw)
Comparative Study
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
A B Raitano et al. Proc Natl Acad Sci U S A. 1995.
Abstract
The leukemogenic tyrosine kinase fusion protein Bcr-Abl activates a Ras-dependent pathway required for transformation. To examine subsequent signal transduction events we measured the effect of Bcr-Abl on two mitogen-activated protein kinase (MAPK) cascades--the extracellular signal-regulated kinase (ERK) pathway and the Jun N-terminal kinase (JNK) pathway. We find that Bcr-Abl primarily activates JNK in fibroblasts and hematopoietic cells. Bcr-Abl enhances JNK function as measured by transcription from Jun responsive promoters and requires Ras, MEK kinase (MAPK/ERK kinase kinase), and JNK to do so. Dominant-negative mutants of c-Jun, which inhibit the endpoint of the JNK pathway, impair Bcr-Abl transforming activity. These findings implicate the JNK pathway in transformation by a human leukemia oncogene.
Similar articles
- GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway.
Shi CS, Tuscano JM, Witte ON, Kehrl JH. Shi CS, et al. Blood. 1999 Feb 15;93(4):1338-45. Blood. 1999. PMID: 9949177 - Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase.
Burgess GS, Williamson EA, Cripe LD, Litz-Jackson S, Bhatt JA, Stanley K, Stewart MJ, Kraft AS, Nakshatri H, Boswell HS. Burgess GS, et al. Blood. 1998 Oct 1;92(7):2450-60. Blood. 1998. PMID: 9746785 - Signal transduction by wild-type and leukemogenic Abl proteins.
Raitano AB, Whang YE, Sawyers CL. Raitano AB, et al. Biochim Biophys Acta. 1997 Dec 9;1333(3):F201-16. doi: 10.1016/s0304-419x(97)00023-1. Biochim Biophys Acta. 1997. PMID: 9426204 Review. No abstract available. - Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection.
Mahlmann S, McLaughlin J, Afar DE, Mohr R, Kay RJ, Witte ON. Mahlmann S, et al. Leukemia. 1998 Dec;12(12):1858-65. doi: 10.1038/sj.leu.2401231. Leukemia. 1998. PMID: 9844916 Review.
Cited by
- A Nucleus-Targeting WT1 Antagonistic Peptide Encapsulated in Polymeric Nanomicelles Combats Refractory Chronic Myeloid Leukemia.
Chen M, Fang X, Du R, Meng J, Liu J, Liu M, Yang Y, Wang C. Chen M, et al. Pharmaceutics. 2023 Sep 12;15(9):2305. doi: 10.3390/pharmaceutics15092305. Pharmaceutics. 2023. PMID: 37765274 Free PMC article. - Profiling of miRNAs and their interfering targets in peripheral blood mononuclear cells from patients with chronic myeloid leukaemia.
Wu SC, Lai SW, Lu XJ, Lai HF, Chen YG, Chen PH, Ho CL, Wu YY, Chiu YL. Wu SC, et al. Front Oncol. 2023 Jul 5;13:1173970. doi: 10.3389/fonc.2023.1173970. eCollection 2023. Front Oncol. 2023. PMID: 37476380 Free PMC article. - The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
Tesileanu CMS, Michaleas S, Gonzalo Ruiz R, Mariz S, Fabriek BO, van Hennik PB, Dedorath J, Dekic B, Unkrig C, Brandt A, Koenig J, Enzmann H, Delgado J, Pignatti F. Tesileanu CMS, et al. Oncologist. 2023 Jul 5;28(7):628-632. doi: 10.1093/oncolo/oyad119. Oncologist. 2023. PMID: 37141403 Free PMC article. Clinical Trial. - A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia.
Limsuwanachot N, Rerkamnuaychoke B, Niparuck P, Singdong R, Kongruang A, Hirunpatrawong P, Siriyakorn T, Yenchitsomanus PT, Siriboonpiputtana T. Limsuwanachot N, et al. J Mass Spectrom Adv Clin Lab. 2023 Apr 13;28:122-132. doi: 10.1016/j.jmsacl.2023.04.002. eCollection 2023 Apr. J Mass Spectrom Adv Clin Lab. 2023. PMID: 37128502 Free PMC article. - Ectopic expression of Nav1.7 in spinal dorsal horn neurons induced by NGF contributes to neuropathic pain in a mouse spinal cord injury model.
Fu Y, Sun L, Zhu F, Xia W, Wen T, Xia R, Yu X, Xu D, Peng C. Fu Y, et al. Front Mol Neurosci. 2023 Mar 3;16:1091096. doi: 10.3389/fnmol.2023.1091096. eCollection 2023. Front Mol Neurosci. 2023. PMID: 36937049 Free PMC article.
References
- J Exp Med. 1994 Jan 1;179(1):167-75 - PubMed
- J Exp Med. 1994 Jun 1;179(6):1855-65 - PubMed
- Cell. 1994 Mar 25;76(6):1025-37 - PubMed
- Science. 1994 Apr 15;264(5157):424-6 - PubMed
- Cancer Res. 1994 May 15;54(10):2563-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous